Fresenius SE & Co KGaA

Chart & Performance

D1W1MN

P/E

—

P/S

1.04

EPS

—

Div Yield, %

2.37%

Shrs. gr., 5y

0.18%

Rev. gr., 5y

-7.83%

Revenues

22.30b

-45.40%

Net income

-594m

CFO

4.46b

+6.15%

Profile

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

URL

https://www.fresenius.com/

IPO date

Dec 18, 1986

Employees

315,233

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	22,299,000 -45.40%	40,840,000 8.85%	37,520,000 3.43%
Cost of revenue	21,057,000	37,726,000	33,467,000
Unusual Expense (Income)
NOPBT	1,242,000	3,114,000	4,053,000
NOPBT Margin	5.57%	7.62%	10.80%
Operating Taxes	477,000	697,000	833,000
Tax Rate	38.41%	22.38%	20.55%
NOPAT	765,000	2,417,000	3,220,000
Net income	(594,000) -143.29%	1,372,000 -24.53%	1,818,000 6.50%
Dividends	(550,000)	(403,000)	(491,000)
Dividend yield
Proceeds from repurchase of equity		20,000	38,000
BB yield
Debt
Debt current	2,581,000	3,036,000	4,772,000
Long-term debt	15,247,000	31,319,000	28,973,000
Deferred revenue	40,000	23,000	30,000
Other long-term liabilities	2,483,000	4,120,000	3,684,000
Net debt	11,710,000	30,888,000	29,725,000
Cash flow
Cash from operating activities	4,456,000	4,198,000	5,078,000
CAPEX	(1,134,000)	(1,917,000)	(2,047,000)
Cash from investing activities	(3,187,000)	(2,607,000)	(2,817,000)
Cash from financing activities	(1,377,000)	(1,604,000)	(1,452,000)
FCF	10,534,000	1,272,000	2,043,000
Balance
Cash	2,562,000	2,345,000	2,746,000
Long term investments	3,556,000	1,122,000	1,274,000
Excess cash	5,003,050	1,425,000	2,144,000
Stockholders' equity	15,325,000	27,895,000	25,262,000
Invested Capital	33,000,950	62,185,000	57,455,000
ROIC	1.61%	4.04%	5.79%
ROCE	3.22%	4.77%	6.63%
EV
Common stock shares outstanding	563,237	561,264	558,156
Price
Market cap
EV
EBITDA	2,720,000	6,087,000	6,720,000
EV/EBITDA
Interest	534,000	694,000	630,000
Interest/NOPBT	43.00%	22.29%	15.54%